Quebec Reveals Details Of Biosimilar Switching Policy

Biosimilars Canada Welcomes Initiative As Other Provinces Pursue Similar Schemes

Quebec has revealed further details of its biosimilar switching policy which is expected to generate annual savings of CAD100m by 2022. The move has received support from Biosimilars Canada, as other Canadian provinces pursue similar initiatives. 

Canada Biosimilars
Savings generated from biosimilar switching policy will be reinvested in Quebec’s healthcare system • Source: Alamy

Biosimilars Canada has welcomed the government of Quebec’s decision to implement and release details of the Canadian province’s biosimilar switching policy, that aims to “increase the use of biosimilar medicines under the Public Prescription Drug Insurance Plan and generate significant savings for the province.”

The Canadian association representing the biosimilar industry noted that Quebec’s biosimilar policy is expected to generate annual savings of CAD100m...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.